Cerebral Lesion, Withdrawal Syndrome
Conditions
Brief summary
The withdrawal syndrome in benzodiazepines and morphine is common in intensive care, the incidence is estimated at 32.1%. Cerebrospatized patients are probably more prone to withdrawal because they require high doses of sedation. Moreover, this syndrome is probably deleterious on the cerebral hemodynamics (high point of the therapeutic management).
Interventions
OTHERVariation of Jasinski score between H0 (stop of sedatives) and H6
To compare the effectiveness of a withdrawal management protocol with the usual management in cerebral patients (Subarachnoid haemorrhage (HSA), stroke and head trauma (CT))
Sponsors
Centre Hospitalier Universitaire, Amiens
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Major Patient * Admitted in Neuroreanimation * Cerebroséé (TC-HSA-AVC) * Mono or multi failing * After a neurosedation ≥ 3 days by hypnotic type benzodiazepine (Midazolam®) and morphinomimetic (Sufentanyl®) in IVSE * Affiliation to Social Security * Agreement of the person of confidence
Exclusion criteria
* Addiction to opiates, cocaine or cannabis * Neurological Pathology Before Hospitalization * Patient suffering from cardiac arrest * Pregnant woman * Sedation window * Patient under tutelage or curatorship or deprived of public law
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| A variation of the Jasinski score between H0 (stop sedation) and H6. This score measures the signs of withdrawal | 3 months |
Countries
France
Outcome results
None listed